Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Survival outcomes in blastic plasmacytoid dendritic cell neoplasm by first-line treatment and stem cell transplant
Seongseok Yun, Onyee Chan, Daniel Kerr, et al.
Blood Advances (2020) Vol. 4, Iss. 14, pp. 3435-3442
Open Access | Times Cited: 39

Showing 1-25 of 39 citing articles:

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need
Naveen Pemmaraju, Hagop M. Kantarjian, Kendra Sweet, et al.
Blood (2022) Vol. 141, Iss. 6, pp. 567-578
Open Access | Times Cited: 31
Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD
Naveen Pemmaraju, Nathaniel R. Wilson, Guillermo Garcia‐Manero, et al.
Blood Advances (2022) Vol. 6, Iss. 10, pp. 3027-3035
Open Access | Times Cited: 30
Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Qaiser Bashir, Denái R. Milton, Uday Popat, et al.
Bone Marrow Transplantation (2021) Vol. 57, Iss. 1, pp. 51-56
Open Access | Times Cited: 32
Novel Therapeutic Approaches in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Era of Targeted Therapy
Nathaniel R. Wilson, Marina Konopleva, Joseph D. Khoury, et al.
Clinical Lymphoma Myeloma & Leukemia (2021) Vol. 21, Iss. 11, pp. 734-740
Closed Access | Times Cited: 29
Unmet Clinical Needs and Management Recommendations for Blastic Plasmacytoid Dendritic Cell Neoplasm: A Consensus-based Position Paper From an Ad Hoc International Expert Panel
Livio Pagano, Pier Luigi Zinzani, Stefano Pileri, et al.
HemaSphere (2023) Vol. 7, Iss. 3, pp. e841-e841
Open Access | Times Cited: 13
Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis
Hemant S. Murthy, Mei‐Jie Zhang, Karen Chen, et al.
Blood Advances (2023) Vol. 7, Iss. 22, pp. 7007-7016
Open Access | Times Cited: 12
Tagraxofusp, a first‐in‐class CD123‐targeted agent: Five‐year postapproval comprehensive review of the literature
Wei‐Ying Jen, Marina Konopleva, Naveen Pemmaraju
Cancer (2024) Vol. 130, Iss. 13, pp. 2260-2271
Closed Access | Times Cited: 4
Blastic plasmacytoid dendritic cell neoplasm (BPDCN): A promising future in the era of targeted therapeutics
Ijele Adimora, Nathaniel R. Wilson, Naveen Pemmaraju
Cancer (2022) Vol. 128, Iss. 16, pp. 3019-3026
Closed Access | Times Cited: 17
Survival outcomes between haploidentical stem cell transplantation and chemotherapy for blastic plasmacytoid dendritic cell neoplasm
Jian Zhou, Feng‐Rong Wang, Shenmiao Yang, et al.
Bone Marrow Transplantation (2025)
Closed Access
Diagnostic approach to blastic plasmacytoid dendritic cell neoplasm: historical perspectives and current understanding
Kana Sakamoto, Kengo Takeuchi
Journal of Clinical and Experimental Hematopathology (2025) Vol. 65, Iss. 1, pp. 1-16
Open Access
TET2 truncating mutations predict a worse outcome in blastic plasmacytoid dendritic cell neoplasm
Hannah C. Beird, C. Cameron Yin, Joseph D. Khoury, et al.
Blood Advances (2023) Vol. 7, Iss. 10, pp. 2000-2003
Open Access | Times Cited: 8
Tagraxofusp for blastic plasmacytoid dendritic cell neoplasm
Marlise R. Luskin, Andrew A. Lane
Haematologica (2023)
Open Access | Times Cited: 8
Blastic Plasmacytoid Dendritic Cell Neoplasm: Progress in Cell Origin, Molecular Biology, Diagnostic Criteria and Therapeutic Approaches
Wei Cheng, Tiantian Yu, Aiping Tang, et al.
Current Medical Science (2021) Vol. 41, Iss. 3, pp. 405-419
Open Access | Times Cited: 18
Conventional Therapeutics in BPDCN Patients—Do They Still Have a Place in the Era of Targeted Therapies?
Margaux Poussard, Fanny Angelot‐Delettre, Éric Deconinck
Cancers (2022) Vol. 14, Iss. 15, pp. 3767-3767
Open Access | Times Cited: 12
Blastic Plasmacytoid Dendritic Cell Neoplasm
Д. В. Кравченко, Д. А. Зиновкин, Denis А. Davydov, et al.
Sultan Qaboos University medical journal (2024) Vol. 24, Iss. 3, pp. 415-417
Open Access | Times Cited: 2
Blastic Plasmacytoid Dendritic Cell Neoplasm, from a Dermatological Point of View
Cosimo Di Raimondo, Flavia Lozzi, Pier Paolo Di Domenico, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 7099-7099
Open Access | Times Cited: 2
Immune-Based Therapeutic Interventions for Acute Myeloid Leukemia
Fabiana Perna, Manuel Espinoza‐Gutarra, Giuseppe Bombaci, et al.
Cancer treatment and research (2022), pp. 225-254
Closed Access | Times Cited: 11
Real-world evidence on tagraxofusp for blastic plasmacytoid dendritic cell neoplasm – collected cases from a single center and case reports
Philipp Faustmann, Jan C. Schroeder, Lucas Mix, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 2
Blastic plasmocitoid dendritic cell neoplasm with leukemic spread: a GIMEMA survey
Caterina Giovanna Valentini, Alfonso Piciocchi, Fabio Facchetti, et al.
Blood Advances (2021) Vol. 5, Iss. 24, pp. 5608-5611
Open Access | Times Cited: 13
Targeting CD123 in BPDCN: an emerging field
Adam J. DiPippo, Nathaniel R. Wilson, Naveen Pemmaraju
Expert Review of Hematology (2021) Vol. 14, Iss. 11, pp. 993-1004
Closed Access | Times Cited: 10
Clinical Insights into the Management of Blastic Plasmacytoid Dendritic Cell Neoplasm
Yumeng Zhang, Lubomir Sokol
Cancer Management and Research (2022) Vol. Volume 14, pp. 2107-2117
Open Access | Times Cited: 7
Recent Advances in the Biology and CD123-Directed Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
Naveen Pemmaraju, Éric Deconinck, Priyanka Mehta, et al.
Clinical Lymphoma Myeloma & Leukemia (2023) Vol. 24, Iss. 4, pp. e130-e137
Open Access | Times Cited: 4
Organ involvement in adults with BPDCN is associated with sun exposure history, TET2 and RAS mutations, and survival
Shai Shimony, Julia Keating, Christopher J. Fay, et al.
Blood Advances (2024) Vol. 8, Iss. 11, pp. 2803-2812
Open Access | Times Cited: 1
Overcoming Tagraxofusp-Erzs Monotherapy Resistance in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in a Real-World Clinical Setting
Prajwal Dhakal, Mario Sy, Grerk Sutamtewagul, et al.
Journal of Immunotherapy and Precision Oncology (2024) Vol. 7, Iss. 3, pp. 205-209
Open Access | Times Cited: 1
CD123-targeted therapy in acute myeloid leukemia
Manuel Espinoza‐Gutarra, Steven D. Green, Joshua F. Zeidner, et al.
Expert Review of Hematology (2021) Vol. 14, Iss. 6, pp. 561-576
Closed Access | Times Cited: 9
Page 1 - Next Page

Scroll to top